Generation Bio Co. (NASDAQ:GBIO) Given Average Recommendation of “Hold” by Brokerages

Shares of Generation Bio Co. (NASDAQ:GBIO) have been given an average recommendation of “Hold” by the six analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $8.00.

GBIO has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Generation Bio in a research report on Tuesday, May 14th. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of Generation Bio in a research report on Tuesday, May 14th.

Hedge Funds Weigh In On Generation Bio

A number of hedge funds have recently bought and sold shares of the business. Kestra Private Wealth Services LLC bought a new position in shares of Generation Bio during the fourth quarter worth approximately $50,000. Los Angeles Capital Management LLC increased its stake in Generation Bio by 315.6% during the 4th quarter. Los Angeles Capital Management LLC now owns 275,834 shares of the company’s stock worth $455,000 after acquiring an additional 209,462 shares during the period. SG Americas Securities LLC raised its holdings in Generation Bio by 260.9% in the 4th quarter. SG Americas Securities LLC now owns 48,470 shares of the company’s stock valued at $80,000 after acquiring an additional 35,040 shares in the last quarter. Bellevue Group AG lifted its position in shares of Generation Bio by 6.8% during the 1st quarter. Bellevue Group AG now owns 3,861,575 shares of the company’s stock valued at $15,717,000 after acquiring an additional 244,495 shares during the period. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Generation Bio during the 1st quarter worth $1,511,000. 95.22% of the stock is owned by institutional investors.

Generation Bio Stock Performance

Shares of NASDAQ GBIO opened at $3.07 on Tuesday. The stock has a 50 day moving average price of $3.39 and a 200 day moving average price of $2.42. The stock has a market capitalization of $204.24 million, a PE ratio of -1.20 and a beta of 2.87. Generation Bio has a 52 week low of $0.86 and a 52 week high of $6.98.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings data on Wednesday, March 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.12). Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. The company had revenue of $2.88 million for the quarter, compared to the consensus estimate of $3.05 million. As a group, research analysts forecast that Generation Bio will post -1.68 EPS for the current year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.